Claims for Patent: 9,029,356

Summary for Patent: 9,029,356

Title:	Substituted indazole derivatives active as kinase inhibitors
Abstract:	Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.
Inventor(s):	Lombardi Borgia; Andrea (Paullo, IT), Menichincheri; Maria (Milan, IT), Orsini; Paolo (Legnano, IT), Panzeri; Achille (Merate, IT), Perrone; Ettore (Boffalora Sopra Ticino, IT), Vanotti; Ermes (Milan, IT), Nesi; Marcella (Saronno, IT), Marchionni; Chiara (Milan, IT)
Assignee:	Nerviano Medical Sciences S.R.L. (Nerviano (MI), IT)
Application Number:	14/212,256
Patent Claims:	1. A compound of formula (Ia), ##STR00132## wherein: R is aryl substituted with one or more halogen; R1, R2 and R3 are hydrogen; Ar is aryl substituted with one or more NR5R6; and R5 and R6 are independently selected from hydrogen and optionally substituted heterocyclyl, or R5 and R6, taken together with the nitrogen atom to which they are bonded, form an optionally substituted heterocyclyl group; or a pharmaceutically acceptable salt thereof. 2. A compound according to claim 1, wherein: R is phenyl substituted with one or more halogen; and Ar is phenyl substituted with one or more NR5R6, wherein R5 and R6 are as defined in claim 3; or a pharmaceutically acceptable salt thereof. 3. A compound according to claim 2, wherein R is phenyl substituted with one or more fluoro, or a pharmaceutically acceptable salt thereof. 4. A compound according to claim 2, wherein: Ar is phenyl substituted with NH(heterocyclyl) and NR5R6; and R5 and R6, together with the nitrogen atom to which they are bonded, form an optionally substituted heterocyclyl group; or a pharmaceutically acceptable salt thereof. 5. A compound according to 4, wherein R is phenyl substituted with one or more fluoro, or a pharmaceutically acceptable salt thereof. 6. A compound according to claim 5, wherein R is difluorophenyl, or a pharmaceutically acceptable salt thereof. 7. A compound according to claim 6, wherein R is 3,5-difluorophenyl, or a pharmaceutically acceptable salt thereof. 8. A compound according to claim 4, wherein R is phenyl substituted with one or more fluoro; and Ar is phenyl substituted with NH(tetrahydropyran-4-yl) and NR5R6, wherein NR5R6 form an optionally substituted piperazin-1-yl group; or a pharmaceutically acceptable salt thereof. 9. A compound according to claim 1, wherein: R is difluorophenyl; and Ar is phenyl substituted with NH(tetrahydropyran-4-yl) and NR5R6, wherein NR5R6 form an optionally substituted piperazin- 1 -yl group; or a pharmaceutically acceptable salt thereof. 10. A compound according to claim 9, wherein said NR5R6 form a piperazin- 1-yl group that is substituted with C.sub.1-C.sub.6 alkyl, or a pharmaceutically acceptable salt thereof. 11. A compound according to claim 10, wherein said NR5R6 form a 4-(C.sub.1-C.sub.6 alkyl)-piperazin-1-yl group, or a pharmaceutically acceptable salt thereof. 12. A compound according to claim 9, wherein R is 3,5-difluorophenyl, or a pharmaceutically acceptable salt thereof. 13. A compound according to claim 10, wherein R is 3,5-difluorophenyl, or a pharmaceutically acceptable salt thereof. 14. A compound according to claim 11, wherein R is 3,5-difluorophenyl, or a pharmaceutically acceptable salt thereof. 15. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, carrier or diluent.